Evofem Biosciences Q3 net sales rise
I'm PortAI, I can summarize articles.
Evofem Biosciences reported a 10% year-over-year increase in Q3 net sales to $5.0 million, with a $1.0 million operating income, reversing a prior year $2.4 million loss. Operating expenses fell 42%, aiding the profit turnaround. The company aims to reduce manufacturing costs by 50% for PHEXX and SOLOSEC, with SOLOSEC submitted for marketing approval in the UAE. No specific financial guidance was provided for future periods.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments